

- *Poster*: Normalization of CPP after TBI protects autoregulation and hippocampal neuronal cell necrosis in female but not male piglets via block of ERK MAPK and IL-6 upregulation. 43rd Society for Neuroscience in Anesthesiology and Critical Care (SNACC) Annual Meeting, San Diego, CA, October 22–23, 2015 (hereafter referred to as the “SNACC 2015 poster”).

- *Poster*: Norepinephrine protects cerebral autoregulation and reduces hippocampal necrosis after traumatic brain injury via block of ERK MAPK and IL-6 in juvenile pigs. Experimental Biology Annual Meeting, San Diego, CA, April 2–6, 2016 (hereafter referred to as the “Experimental Biology 2016 poster”).

- *Poster*: Epinephrine blocks JNK MAPK, protects autoregulation and reduces histopathology after brain injury by age and sex. Neurotrauma 2016—The 34th Annual Symposium of the National Neurotrauma Society, Lexington, KY, June 26–29, 2016 (hereafter referred to as the “Neurotrauma Society 2016 poster”).

- R35 NS116805–01, “Brain-heart relationships in outcomes after traumatic brain injury,” submitted to NINDS, NIH, on July 26, 2019, administratively withdrawn on March 3, 2020.

- R01 NS121149–01, “Brain Heart Interactions and Vascular Contribution to Cognitive Outcome After TBI,” submitted to NINDS, NIH, on June 5, 2020, administratively withdrawn on November 1, 2022.

- R01 HL139506–01, “tPA, NMDA receptor excitotoxicity, and outcome after stroke,” submitted to NHLBI, NIH, on February 6, 2017, administratively withdrawn on July 2, 2019.

- NINDS, NIH, R01 NS090998–02, –03, –04, and –05 grant progress reports, “Pressor Choice Influences Protection of Autoregulation in Brain Injury,” Funding Period: September 1, 2015–August 31, 2020.

Specifically, ORI found that Respondent intentionally and knowingly:

- Reused histopathology slides to falsely represent the controls for hippocampal neurons exposed to fluid percussion injury (FPI) and treated with norepinephrine (NE), phenylephrine (PHE), epinephrine (EPI), or dopamine (DA) in distinct experiments performed at different times in Figures 7A, 7B, 7C, 7E, 7G, and 7H of *Ped Crit Care Med.* 2016, Figures 5A, 5B, 5C, 5D, 5G, and 5H of the *Ped Crit Care Med.* 2019 manuscript, Figures 5A, 5B, 5C, 5E, 5G, and 5H of *Pediatr Res.* 2017, Figures 6A, 6B, 6C, 6G, and 6H of *J Neurotrauma* 2017, Figures 7A, 7B, 7C, and 7E of *J*

Neurotrauma 2016, and Figures 5A, 5B, 5C, 5D, and 5E of *Brain Res.* 2017.

- Reused the histopathology slides representing necrotic neurons after FPI treatment with NE in Figure 7E of *Ped Crit Care Med.* 2016 and relabeled the panel to falsely represent necrotic neurons after FPI treatment with PHE in Figure 5D of the *Ped Crit Care Med.* 2019 manuscript.

- Reused and relabeled the histograms to falsely represent traumatic brain injury responses, as represented by necrotic hippocampal neurons, in piglets of different ages and/or genders exposed to different therapeutic agents in Figure 5I of the *Ped Crit Care Med.* 2019 manuscript, Figure 7I of *Ped Crit Care Med.* 2016, Figure 7G of *J Neurotrauma* 2016, Figure 7G of *J Neurotrauma* 2017, and Figure 5I of *Brain Res.* 2017.

- Reused and relabeled histograms to falsely represent the pial artery response to different therapeutic agents for traumatic brain injury in piglets of different ages and genders in Figure 3 of *Pediatr Res.* 2017, Figures 3A and 3B of *Ped Crit Care Med.* 2016, and Figures 3 and 5I of *Brain Res.* 2017.

- Falsified and/or fabricated the sham condition, experimental methods, neuronal count methodology, piglet number, data, and statistics reported in *Ped Crit Care Med.* 2016, *J Neurotrauma* 2016, *J Neurotrauma* 2017, *Pediatr Res.* 2017, *Brain Res.* 2017, and the *Ped Crit Care Med.* 2019 manuscript.

- Reported falsified data, results, and conclusions highlighting the roles that age and gender have in the treatment of traumatic brain injury from *Ped Crit Care Med.* 2016, *J Neurotrauma* 2016, *J Neurotrauma* 2017, *Brain Res.* 2017, and *Pediatr Res.* 2017 in *Exp. Neuro.* 2019.

- Reported falsified results from *Ped Crit Care Med.* 2016, *J Neurotrauma* 2016, *J Neurotrauma* 2017, and *Brain Res.* 2017 and in the SNACC 2016 poster, Experimental Biology 2016 poster, Neurotrauma 2016 poster in progress reports R01 NS090998–02, –03, –04, and –05.

- Reported falsified results of the vasoactive agents NE, EPI, PHE, and DA on autoregulation and hippocampal neuronal necrosis in piglets of different ages and genders after a stroke or traumatic brain injury in Figures 4A, 4B, 5A, 5B, 6A, and 6B of R35 NS116805–01 and R01 NS121149–01, Figures 3A, 3B, 3G, and 3H of R01 HL139506–01, and the Research Strategy section of R35 NS116805–01.

Respondent entered into a Voluntary Exclusion Agreement (Agreement) and voluntarily agreed to the following:

(1) Respondent will exclude himself voluntarily for a period of seven (7)

years beginning on June 19, 2023 (the “Exclusion Period”), from any contracting or subcontracting with any agency of the United States Government and from eligibility for or involvement in nonprocurement or procurement transactions referred to as “covered transactions” in 2 CFR parts 180 and 376 (collectively the “Debarment Regulations”).

(2) During the Exclusion Period, Respondent will exclude himself voluntarily from serving in any advisory or consultant capacity to PHS including, but not limited to, service on any PHS advisory committee, board, and/or peer review committee.

(3) Respondent will request that the following paper be corrected or retracted:

- *Exp Neurol.* 2019 Jul;317:291–7. doi: 10.1016/j.expneurol.2019.03.015.

Respondent will copy ORI and the Research Integrity Officer at UPENN on the correspondence with the journal.

Dated: July 3, 2023.

Sheila Garrity,

Director, Office of Research Integrity, Office of the Assistant Secretary for Health.

[FR Doc. 2023–14426 Filed 7–6–23; 8:45 am]

BILLING CODE 4150–31–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Committee on Vital and Health Statistics; Meeting

AGENCY: Centers for Disease Control and Prevention, HHS.

ACTION: Notice of meeting.

SUMMARY: Pursuant to the Federal Advisory Committee Act, the Department of Health and Human Services (HHS) announces the following advisory committee meeting. This meeting is open to the public. The public is welcome to attend in person or virtually by following the instructions posted on the website: <https://ncvhs.hhs.gov/meetings/full-committee-meeting-14/>.

Name: National Committee on Vital and Health Statistics (NCVHS) Meeting.

DATES:

Wednesday, July 19, 2023: 9:15 a.m.–5:30 p.m. EDT.

Thursday, July 20, 2023: 8:45 a.m.–2:45 p.m. EDT.

ADDRESSES: Hubert H. Humphrey Building (HHS Headquarters), 200 Independence Avenue SW, Room 505–A, Washington, DC 20201.

Registration is not required for in-person attendance; however, it is strongly encouraged to expedite entry through building security. A valid form

of U.S. ID is required for in-person attendance.

FOR FURTHER INFORMATION CONTACT:

Substantive program information may be obtained from Rebecca Hines, MHS, Executive Secretary, NCVHS, National Center for Health Statistics, Centers for Disease Control and Prevention, 3311 Toledo Road, Hyattsville, Maryland 20782, or via electronic mail to vgh4@cdc.gov; or by telephone (301) 458-4715. Summaries of meetings and a roster of Committee members are available on the NCVHS website <https://ncvhs.hhs.gov/>, where further information including an agenda and instructions to access the broadcast of the meeting will be posted.

Should you require reasonable accommodation, please telephone the CDC Office of Equal Employment Opportunity at (770) 488-3210 as soon as possible.

SUPPLEMENTARY INFORMATION:

Purpose: As outlined in its Charter, the National Committee on Vital and Health Statistics assists and advises the Secretary of HHS on health data, data standards, statistics, privacy, national health information policy, and the Department's strategy to best address those issues.¹ Under the Health Insurance Portability and Accountability Act of 1996 (HIPAA),² NCVHS advises the Secretary on administrative simplification standards, including those for privacy, security, adoption and implementation of transaction standards, unique identifiers, code sets, and operating rules adopted under the Patient Protection and Affordable Care Act (ACA).³

The meeting agenda will include time to introduce six new members recently appointed to serve on the Committee, continue with activities outlined in the NCVHS 2023 workplan, and hold discussions on several health data policy topics, including a briefing on conversational artificial intelligence (AI).

The NCVHS Workgroup on Timely and Strategic Action to Inform ICD-11 Policy for morbidity will report to the full Committee on activities leading up to the August 3, 2023, Expert Roundtable meeting. The National Center for Health Statistics will provide an update on implementation of ICD-11 for mortality.

The Subcommittee on Privacy, Confidentiality and Security will host panel briefings on Privacy and Reproductive Health with invited experts. The Subcommittee on Standards will report on its "Convergence 2.0" activities in light of completion of recommendations to the Department approved at the June 14, 2023, meeting of the full Committee. Finally, the Committee will allot time to discuss language for inclusion in the Committee's 2023 Report to Congress.

The Committee will reserve time on the agenda for public comment. Meeting times and topics are subject to change. Please refer to the agenda posted on the NCVHS website for updates: <https://ncvhs.hhs.gov/meetings/full-committee-meeting-14/>.

Sharon Arnold,

Associate Deputy Assistant Secretary, Office of Science and Data Policy, Office of the Assistant Secretary for Planning and Evaluation.

[FR Doc. 2023-14284 Filed 7-6-23; 8:45 am]

BILLING CODE 4150-05-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Heart, Lung, and Blood Institute; Notice of Closed Meetings

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel; Mentored Career Development Awards.

Date: August 2, 2023.

Time: 10:00 a.m. to 2:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Rockledge I, 6705 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Kristin Goltry, Ph.D., Scientific Review Officer, Office of Scientific Review/DERA, National Heart, Lung, and Blood Institute, National Institutes of Health, 6705 Rockledge Drive, Room 209-B, Bethesda, MD 20892, (301) 435-0297, goltrykl@mail.nih.gov.

Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel; NHLBI Emerging Investigator Award (R35 EIA) Review Meeting.

Date: August 3, 2023.

Time: 10:00 a.m. to 6:30 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Rockledge I, 6705 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Kazuyo Kegan, Ph.D., Scientific Review Officer, Office of Scientific Review/DERA, National Heart, Lung, and Blood Institute, National Institutes of Health, 6705 Rockledge Drive, Room 208-T, Bethesda, MD 20892, (301) 402-1334, kazuyo.kegan@nih.gov.

Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel; NHLBI Mentored Career Development K-Awards.

Date: August 3, 2023.

Time: 10:30 a.m. to 2:30 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Rockledge I, 6705 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Fungai Chanetsa, Ph.D., MPH, Scientific Review Officer, Office of Scientific Review/DERA, National Heart, Lung, and Blood Institute, National Institutes of Health, 6705 Rockledge Drive, Room 206-B, Bethesda, MD 20817, (301) 402-9394, fungai.chanetsa@nih.gov.

Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel; Catalyze Enabling Technologies.

Date: August 4, 2023.

Time: 10:00 a.m. to 2:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Rockledge I, 6705 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Kristin Goltry, Ph.D., Scientific Review Officer, Office of Scientific Review/DERA, National Heart, Lung, and Blood Institute, National Institutes of Health, 6705 Rockledge Drive, Room 209-B, Bethesda, MD 20892, (301) 435-0297, goltrykl@mail.nih.gov.

Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel; Catalyze Product Definition.

Date: August 7, 2023.

Time: 10:00 a.m. to 4:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Rockledge I, 6705 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Kristin Goltry, Ph.D., Scientific Review Officer, Office of Scientific Review/DERA, National Heart, Lung, and Blood Institute, National Institutes of Health, 6705 Rockledge Drive, Room 209-B, Bethesda, MD 20892, (301) 435-0297, goltrykl@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases

¹ The original authorities of NCVHS are described at 42 U.S. Code § 242k.

² Public Law 104-191, 110 Stat. 1936 (Aug. 21, 1996), available at <https://www.congress.gov/104/plaws/publ191/PLAW-104publ191.pdf>.

³ Public Law 111-148, 124 Stat. 119 (Mar. 23, 2010), available at <https://www.congress.gov/111/plaws/publ148/PLAW-111publ148.pdf>.